Oncolytics Biotech, Inc.

Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Oncolytics Biotech reports strong earnings and growth opportunities ahead

Oncolytics Biotech's Q4 2022 earnings call highlighted notable progress, strong financials, and promising trial outcomes.
The company faces challenges in trial design and collaboration agreements but is well-positioned for growth.
Opportunities lie in upcoming trial readouts, business development efforts, and expansion into Asian markets.

Oncolytics Biotech progresses in key trials, eyes market impact

Oncolytics Biotech, Inc. demonstrated progress in key trials and financial stability, positioning itself for potential market impact.
Strategic focus on validating data, understanding mechanisms of action, and pursuing efficient registration pathways underscores the company's commitment to innovation.
Challenges in managing trial outcomes and sustaining growth require careful navigation, but opportunities in diversification and market expansion offer avenues for success.
Overall, the company's emphasis on strategic milestones and licensing opportunities signals a proactive approach to maximizing value and market potential.

Oncolytics Biotech reports positive Q2 results and eyes growth opportunities

Oncolytics Biotech's Q2 2023 earnings call highlighted positive progress in clinical trials and strong financial performance.
The company's focus on research and development, business development efforts, and commitment to expansion present growth opportunities.
Challenges include trial execution concerns, complexities in combining treatments, and regulatory pathways that need to be navigated.

Oncolytics Biotech reports positive Q3 results and eyes strategic partnerships

Oncolytics Biotech demonstrated strong performance and promising outcomes in Q3 2023, with pela showing success in clinical trials for pancreatic and colorectal cancers.
While facing challenges in data clarity and market positioning, the company has opportunities to expand treatments, collaborations, and advance regulatory studies.
Overall, the company's financial stability, clinical progress, and strategic partnerships position it well for future growth and advancements in cancer treatments.

Oncolytics Biotech reports robust earnings, eyes oncology expansion in 2024

Oncolytics Biotech, Inc. showcased strong financial performance and progress in becoming a late-stage cancer company.
While facing challenges in research validation and managing operating costs, the company is well-positioned for growth.
Opportunities lie in validating survival benefits, expanding pela's market potential, and advancing strategic objectives in oncology.
Overall, Oncolytics' focus on innovation, financial prudence, and clinical advancements sets a positive trajectory for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

- Clinical AWARE-1 trial achieves primary endpoint and confirms that pelareorep is an immunotherapeutic agent which synergizes with checkpoint inhibitors: Validation of clinical development strategy in breast cancer - Phase 2 BRACELET-1 (breast cancer) trial remains on track for full enrollment in Q4 2021 - Highly encouraging clinical proof-of-concept data in metastatic pancreatic cancer demonstrate pelareorep's broad applicability to a number of different tumor types - Strong financial foundation with approximately $50.8 million in cash on hand and cash runway into 2023 - Management hosting conference call and webcast today at 8:00 a.m. ET SAN DIEGO and CALGARY, AB, Aug. 6, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced its financial results and development highlights for the quarter ended June 30, 2021.

Oncolytics Biotech® Reports 2021 Second Quarter Development Highlights and Financial Results

SAN DIEGO and CALGARY, AB, Aug. 6, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference, which is taking place virtually from August 10-12, 2021. Presentation details are listed below.

Oncolytics Biotech® to Participate in Virtual Fireside Chat at the Canaccord Genuity 41st Annual Growth Conference

Conference call and webcast to take place on Friday, August 6, 2021, at 8:00 a.m. ET SAN DIEGO and CALGARY, AB, July 22, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Friday, August 6, 2021, at 8:00 a.m.

Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights

SAN DIEGO and CALGARY, AB, June 30, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will present a corporate overview at the Ladenburg Thalmann Healthcare Conference, which is taking place virtually from July 13-14, 2021. Presentation details are listed below.

Oncolytics Biotech® to Present at the Ladenburg Thalmann Healthcare Conference

Merck

Oncolytics Biotech Inc (NASDAQ: ONCY) has announced new data from Phase 2 trial evaluating pelareorep in combination with Merck & Co Inc (NYSE: MRK) Keytruda (pembrolizumab) in pancreatic cancer. Data will be presented at the 2021 American Society of Clinical Oncology Annual Meeting.

Oncolytics Pelareorep/Pembrolizumab Combo Therapy Shows Anti-Cancer Activity In Pancreatic Cancer

The stock price of Oncolytics Biotech, Inc. (NASDAQ: ONCY) increased by over 4% pre-market. This is why it happened.

Oncolytics Biotech (ONCY) Stock: Over 4% Increase Pre-Market Explanation

SAN DIEGO, Calif. and CALGARY, AB, May 20, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced clinical and biomarker data demonstrating clinical proof-of-concept for pelareorep-checkpoint inhibitor combination therapy in pancreatic cancer.

Oncolytics Biotech® Announces Clinical and Biomarker Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Checkpoint Inhibitor Combination in Pancreatic Cancer

Fireside chat to take place on Wednesday, May 19 at 5:25 pm ET SAN DIEGO and CALGARY, AB, May 13, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference, which is taking place virtually from May 18-20, 2021. Presentation details are listed below.

Oncolytics Biotech® to Participate in Virtual Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference

- AWARE-1 clinical data validate clinical development strategy by confirming pelareorep's anti-tumor mechanism of action known to be associated with improved patient outcomes and ability to synergize with checkpoint inhibitors - Preclinical studies show that pelareorep's synergistic benefits extend across multiple classes of immunotherapeutic agents, including novel CAR T approaches in solid tumors - Phase 2 BRACELET-1 clinical trial on track for full enrollment in Q4-2021 - Strong financial foundation with over $50 million in cash on hand and cash runway to Q4-2022 SAN DIEGO and CALGARY, AB, May 7, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced its financial results and development highlights for the quarter ended March 31, 2021. All dollar amounts are expressed in Canadian currency unless otherwise noted.

Oncolytics Biotech® Reports 2021 First Quarter Development Highlights and Financial Results

Management will also provide its annual corporate update after the conclusion of the meeting SAN DIEGO, Calif. and CALGARY, AB, April 30, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), (the "Company") today announced that its upcoming 2021 Annual General Meeting (the "Meeting") will be held virtually at 12:00 p.m.

Oncolytics Biotech® Announces Annual General Meeting

SAN DIEGO and CALGARY, AB, April 29, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the acceptance of an abstract discussing its pancreatic adenocarcinoma trial at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place virtually from June 4 – 8, 2021. Details on the abstract and a corresponding poster presentation are shown below.

Oncolytics Biotech® Announces Upcoming Presentation at the American Society of Clinical Oncology Annual Meeting

Oncolytics Biotech Inc (NASDAQ: ONCY), together with SOLTI, has announced new clinical data from the AWARE-1 window-of-opportunity breast cancer study evaluating pelareorep plus checkpoint blockade therapy.  These data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2021.

Oncolytics Biotech's Pelareorep Associated With Therapeutic Efficacy, Improved Clinical Outcomes In Breast Cancer

- Pelareorep and atezolizumab synergize the anti-cancer immune response in HR+/HER2- breast cancer patients - Pelareorep alone and with checkpoint blockade converts tumors to PD-L1 positive classification - Oncolytics validates that pelareorep significantly improves immunotherapies - Company management hosting a KOL event today at 2:00 pm ET SAN DIEGO and CALGARY, Alberta, April 12, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), together with SOLTI, recently announced new clinical data from the AWARE-1 window-of-opportunity breast cancer study showing patients receiving pelareorep plus checkpoint blockade therapy met the trial's primary endpoint. These data are featured in an electronic poster at the American Association for Cancer Research (AACR) Annual Meeting 2021 during Week 1, which is taking place virtually from April 10-15, 2021.

Oncolytics Biotech® and SOLTI Achieve Primary Endpoint in AWARE-1 Study

SAN DIEGO and CALGARY, AB, April 12, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) recently announced preclinical data highlighting pelareorep's ability to synergize with multiple classes of anti-cancer agents. The data are featured in two electronic poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021.

Oncolytics Biotech® Presents Preclinical Data on Pelareorep-based Combination Therapies at the AACR Annual Meeting

SAN DIEGO and CALGARY, Alberta, April 8, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Dr. Matt Coffey, the Company's President and Chief Executive Officer, will be participating in a panel discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference. Details on the panel discussion are provided below.

Oncolytics Biotech® to Participate in a Panel Discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference

Today, we take a look at an 'off the radar' development concern named Oncolytics Biotech. The company's primary drug candidate is advancing in several trials in combination with various checkpoint inhibitors targeting different forms of tumors.

Our First Look At Oncolytics Biotech

SAN DIEGO and CALGARY, AB, April 5, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a Key Opinion Leader (KOL) webinar discussing AWARE-1 data, the immunotherapeutic effects of pelareorep in breast cancer, and its synergistic activity with CAR T cells in solid tumors. The webinar will take place on Monday, April 12, 2021 at 2:00 pm ET.

Oncolytics Biotech® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T Cells in Solid Tumors

Oncolytics Biotech (ONCY) has moved higher as of late, but there could definitely be trouble on the horizon for this company

Oncolytics Biotech (ONCY) Enters Overbought Territory

SAN DIEGO and CALGARY, AB, March 10, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will present updated clinical data from its AWARE-1 window-of-opportunity study in patients with early-stage breast cancer, as well as results from preclinical studies evaluating pelareorep-based combination therapies, in poster presentations during Week 1 of the American Association for Cancer Research (AACR) Annual Meeting 2021, taking place virtually from April 10-15, 2021. Details on the posters and corresponding abstracts are shown below.

Oncolytics Biotech® Announces Upcoming Presentations at the AACR Annual Meeting

Oncolytics Biotech Inc. (ONCY) CEO Dr. Matt Coffey on Q4 2020 Results - Earnings Call Transcript

SAN DIEGO, Calif. and CALGARY, AB, March 5, 2021 /PRNewswire/ ---- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it has entered into an at-the-market (ATM) equity offering sales...

Oncolytics Biotech® Establishes New At-The-Market Facility

- New clinical data highlight pelareorep's potential to boost the effectiveness of checkpoint inhibitors - Clinical demonstration of pelareorep reversing immunosuppressive tumor microenvironments - On track to report clinical biomarker and safety data in breast cancer in 2021 - Strong...

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights

SAN DIEGO, Calif. and CALGARY, AB, Feb. 26, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Friday, March 5, 2021, at 8:30 am ET to discuss a corporate update and financial results for the fourth...

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Operational Highlights

Bausch Health Companies Inc

DiaMedica Therapeutics Inc

iBio

Outlook Therapeutics Inc

iBio (NYSE: IBIO) shares are trading lower Wednesday after the company reported second-quarter earnings results. iBio's main area of business is plant-based protein expression technologies for vaccines and therapeutic proteins and developing and commercializing select biopharmaceutical product candidates.

Why Bausch Health, Oncolytics Biotech, And More Are Moving Today

The stock price of Oncolytics Biotech, Inc. (NASDAQ: ONCY) is trading at over 60% pre-market. This is why it happened.

News for Oncolytics Biotech, Inc. Stock (ONCY)